Pfizer Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PFIZER.NS | AZN | SANOFI.NS | MRK | GLAXO.BO | SNY | |
|---|---|---|---|---|---|---|
| Market cap | 176.44B | 293.14B | 78.12B | 370.96B | 423.63B | 113.74B |
| P/E (TTM) | 23.2 | 26.7 | 21.4 | 151.9 | 44.4 | 23.6 |
| Forward P/E | 18.8 | 16.7 | 19.1 | 16.7 | 36.9 | 8.9 |
| Price/book | 4.0 | 5.7 | 9.5 | 8.9 | 24.8 | 1.4 |
| Dividend yield | 1.96% | 1.69% | 3.56% | 2.26% | 1.75% | 5.10% |
| 1-year change | −24.33% | +12.81% | −28.75% | +75.29% | +6.17% | −4.08% |
| Today | +0.58% | +2.79% | −1.70% | +3.93% | −1.26% | +4.72% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All PFIZER.NS news ›Pfizer (PFE) Gets a Hold from J.P. Morgan
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. Schott covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Pfizer. According to TipRanks,…
Buy Pfizer; target of Rs 4800: ICICI Securities
Moneycontrol.com Buy Pfizer; target of Rs 4800: ICICI Securities ICICI Securities's research report on Pfizer Pfizer delivered a revenue beat in Q2FY27, though EBITDA and PAT were in line with our expectations. Revenue advanced ~13.2%…
Pfizer: 3 Key Takeaways for Long-Term Investors
The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue. New treatments and recent acquisitions are generating immediate sales growth that buffers…
Chris Boshoff։ Pfizer Highlights Q3 R&D Progress Across Oncology, Internal Medicine, Vaccines, and Immunology
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn: “Our Q3 R&D progress reflects the work underway to advance potential medicines and vaccines for patients across Oncology,…
Pfizer to Prioritize European Market for Lyme Disease Vaccine Launch in November 2026
Pfizer plans to prioritize the European market for the launch of its upcoming Lyme disease vaccine, citing its existing infrastructure for tick-borne encephalitis treatments in the region. While the company intends to address the rising…
United Therapeutics buys out Pfizer royalties linked to lung disease therapy
United Therapeutics buys out Pfizer royalties (PFE:NYSE) Seeking Alpha United Therapeutics (UTHR) traded higher in premarket trading on Wednesday after the company, alongside its Q3 2026 results, announced the acquisition of Pfizer’s (PFE)…
Pfizer raises 2026 outlook to $62B-$64B revenue and $2.95-$3.05 adjusted EPS, targeting high single-digit revenue CAGR from 2028-2033
Pfizer Q3 2026 earnings highlight raised guidance, strong revenue growth, and pipeline updates amid 2027 pricing and LOE risks. Earnings Call Insights: Pfizer (PFE) Q3 2026 - "I'm pleased with another strong quarter for Pfizer." (Chairman…
Pfizer Inc. : UBS sticks Neutral
www.marketscreener.com Pfizer Inc. : UBS sticks Neutral Published on 11/04/2026 at 10:01 am EST Latest news about Pfizer Inc. Income Statement and Estimates Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC May 05, 2026 at 05:57 pm EDT…
Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US
Pfizer’s Valneva-partnered Lyme disease vaccine is nearing a regulatory submission, with interest in preventative options against the tick-borne disease rising around the world. But the FDA won’t be its first stop. Rather, Europe will…
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite launching a new trial. When stock prices and headlines point in opposite directions across the sector, something…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- 247wallst.com22
- fool.com20
- seekingalpha.com16
- marketscreener.com15
- theglobeandmail.com14
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.